drugset / Trial / NCT03868709

Prophylactic Penehyclidine Hydrochloride Inhalation and 3-year Outcome After Surgery

NCT03868709

Phase 4 Completed 864 enrolled Peking University First Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Postoperative pulmonary complications (PPCs) are major causes of postoperative morbidity, mortality, and prolonged hospital stay.The incidence of PPCs may be as high as 41% to 75% in high-risk patients. Bronchodilator is frequently used in high-risk patients to prevent PPCs. Penehyclidine is a new anticholinergic agent which selectively block M1 and M3 receptors. A previous randomized controlled trial tested the effect of prophylactic penehyclidine inhalation on the incidence of PPCs in high-risk patients. The purpose of this 3-year follow-up study is to investigate whether prophylactically penehyclidine hydrochloride inhalation can affect the 3-year outcomes of patients recruited in the previous randomized controlled trial.

Timeline

Start
2019-03-12
Primary completion
2021-12-01
Completion
2021-12-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Penehyclidine Small molecule 0.5 mg Inhaled

Indications

No indication recorded.